These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37504249)

  • 1. Establishment of a Novel Anti-CD44 Variant 10 Monoclonal Antibody C
    Ishikawa K; Suzuki H; Kaneko MK; Kato Y
    Curr Issues Mol Biol; 2023 Jun; 45(7):5248-5262. PubMed ID: 37504249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Novel Anti-CD44 Variant 7/8 Monoclonal Antibody, C
    Suzuki H; Ozawa K; Tanaka T; Kaneko MK; Kato Y
    Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas.
    Ishikawa K; Suzuki H; Ohishi T; Li G; Tanaka T; Kawada M; Ohkoshi A; Kaneko MK; Katori Y; Kato Y
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Anti-CD44 Variant 9 Monoclonal Antibody C
    Tawara M; Suzuki H; Goto N; Tanaka T; Kaneko MK; Kato Y
    Curr Issues Mol Biol; 2023 Apr; 45(4):3658-3673. PubMed ID: 37185762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Novel Anti-CD44 Variant 4 Monoclonal Antibody C
    Suzuki H; Tanaka T; Goto N; Kaneko MK; Kato Y
    Curr Issues Mol Biol; 2023 Feb; 45(3):1875-1888. PubMed ID: 36975491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Anti-CD44 Variant 3 Monoclonal Antibody C
    Suzuki H; Kitamura K; Goto N; Ishikawa K; Ouchida T; Tanaka T; Kaneko MK; Kato Y
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Novel Anti-CD44 Variant 6 Monoclonal Antibody C
    Ejima R; Suzuki H; Tanaka T; Asano T; Kaneko MK; Kato Y
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Novel Anti-CD44 Variant 5 Monoclonal Antibody C
    Kudo Y; Suzuki H; Tanaka T; Kaneko MK; Kato Y
    Antibodies (Basel); 2023 Apr; 12(2):. PubMed ID: 37218897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Novel Anti-CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas.
    Goto N; Suzuki H; Tanaka T; Asano T; Kaneko MK; Kato Y
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C
    Suzuki H; Goto N; Tanaka T; Ouchida T; Kaneko MK; Kato Y
    Antibodies (Basel); 2023 Jul; 12(3):. PubMed ID: 37489367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C
    Yamada S; Itai S; Nakamura T; Yanaka M; Kaneko MK; Kato Y
    Biochem Biophys Rep; 2018 Jul; 14():64-68. PubMed ID: 29872736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epitope Mapping of an Anti-CD44v4 Monoclonal Antibody (C
    Suzuki H; Tawara M; Hirayama A; Goto N; Tanaka T; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2024 Jun; 43(3):85-89. PubMed ID: 38507669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epitope Mapping of the Anti-CD44 Monoclonal Antibody (C
    Asano T; Kaneko MK; Takei J; Tateyama N; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Aug; 40(4):156-161. PubMed ID: 34283655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope Mapping of the Anti-CD44 Monoclonal Antibody (C
    Takei J; Asano T; Suzuki H; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Oct; 40(5):219-226. PubMed ID: 34678095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Novel Epitope Mapping System: RIEDL Insertion for Epitope Mapping Method.
    Asano T; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Aug; 40(4):162-167. PubMed ID: 34424761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interplay between Podoplanin, CD44s and CD44v in Squamous Carcinoma Cells.
    Montero-Montero L; Renart J; Ramírez A; Ramos C; Shamhood M; Jarcovsky R; Quintanilla M; Martín-Villar E
    Cells; 2020 Sep; 9(10):. PubMed ID: 33003440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of CD44 variant expression in oral, head and neck squamous cell carcinomas using a triple approach and its clinical significance.
    Athanassiou-Papaefthymiou M; Shkeir O; Kim D; Divi V; Matossian M; Owen JH; Czerwinski MJ; Papagerakis P; McHugh J; Bradford CR; Carey TE; Wolf GT; Prince ME; Papagerakis S
    Int J Immunopathol Pharmacol; 2014; 27(3):337-49. PubMed ID: 25280025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel CD44 v3 isoform is involved in head and neck squamous cell carcinoma progression.
    Franzmann EJ; Weed DT; Civantos FJ; Goodwin WJ; Bourguignon LY
    Otolaryngol Head Neck Surg; 2001 Apr; 124(4):426-32. PubMed ID: 11283501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitigation of delayed-type hypersensitivity reactions by a CD44 variant isoform v3-specific antibody: blockade of leukocyte egress.
    Seiter S; Engel P; Föhr N; Zöller M
    J Invest Dermatol; 1999 Jul; 113(1):11-21. PubMed ID: 10417612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD44 variant isoforms in head and neck squamous cell carcinoma progression.
    Wang SJ; Wong G; de Heer AM; Xia W; Bourguignon LY
    Laryngoscope; 2009 Aug; 119(8):1518-30. PubMed ID: 19507218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.